PPARA and metabolic dysfunction-associated steatohepatitis: The protective effect of PPARα was further demonstrated by treating fibrotic APOE2KI811A mice with the PPARα agonist fenofibrate, which protected mice from NASH by reducing both steatosis and hepatic macrophage accumulation [10].